Antiganglioside antibodies explained
Antiganglioside antibodies that react to self-gangliosides are found in autoimmune neuropathies. These antibodies were first found to react with cerebellar cells.[1] These antibodies show highest association with certain forms of Guillain–Barré syndrome.
Antibodies to ganglioside subtypes
Autoantigenic gangliosides that are currently known are GD3, GM1, GQ3 and GT1.
Anti-GD3
Anti-GD3 antibodies have been found in association with specific forms of Guillain–Barré syndrome. In vivo studies of isolated anti-GM1 and GD3 antibodies indicate the antibodies can interfere with motor neuron function.[2] Anti-GD1a antibodies were highly associated acute motor axonal neuropathy while high titers of anti-GM1 were more frequent indicating that GD1a possibly targets the axolemma and nodes of Ranvier[3] most of the Ab+ patients had C. jejuni infections. Patients with Anti-GalNAc-GD1a antibodies were less common but had more severe disease (rapidly progressive, predominantly distal weakness).[4]
Anti-GM1
Levels of anti-GM1 antibodies are elevated in patients with various forms of dementia.[5] Antibodies levels correlate with more severe Guillain–Barré syndrome.[6] Levels of anti-GM1 antibodies are especially elevated in patients with prodromal diarrhea.[7] Titers to GM1 in other diseases (rheumatoid arthritis, primary Sjögren's syndrome and systemic lupus erythematosus) was also elevated.[8] Additionally highly significant association was found with rheumatoid arthritis and peripheral neuropathies.[9] Conflicting evidence suggests no significant elevation in motor neuron neuropathy but marginally elevated IgA in sensory neuron neuropathies.[10] The autoimmune role of anti-GM1 is still unclear. Multifocal motor neuropathy (MMN) with conduction block is closely related to CIDP (chronic inflammatory demyelinating polyneuropathy). Anti-GM1 antibodies are positive in around 80% of cases. MMN will present with asymmetrical motor neuropathy where reflexes are usually preserved (or slightly increased), affecting upper limb more than lower limb. MMN is potentially treatable with immunomodulation.
Anti-GQ1b
Anti-GQ1b were typically described in Miller-Fisher syndrome. This presents with the classical triad of ataxia, areflexia and ophthalmoplegia. The clinical spectrum of disorders associated with anti-GQ1b now is also recognized to include, Bickerstaff brainstem encephalitis, Guillain-Barré syndromewith ophthalmoplegia, and acute ophthalmoplegia without ataxia.[11] Studies of these antibodies reveal large disruption of the Schwann cells.[12] [7]
Triggering agents
Microbial agents include: Campylobacter jejuni and Mycoplasma pneumoniae.[13]
Campylobacter jejuni
Antibodies to a GM1 epitope as well as to one with the GT1a or GD3 epitope were found in different strains of Campylobacter jejuni[14] and patients with Guillain–Barré syndrome have a high occurrence of C. jejuni infection.[15] Many studies indicate that C. jejuni may be causative for a subset of some forms of neuropathies.
Coeliac disease
Antibodies to ganglioside are found to be elevated in coeliac disease.[16] Recent studies showthat gliadin can cross-link to gangliosides in a transglutaminase independent manner, indicating that gliadin specific T-cell could present these antigens to the immune system.[17]
Immunoglobin isotypes
IgG. In multiple sclerosis, antibodies to GM1 are dominated by the IgG1, IgG3 and IgG4.[18] Also anti-GM1 IgG has been identified in Guillain–Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy.[19] while controlled studies failed to find any significant association with Motor neuron disease.[20]
IgA. IgA to gangliosides have been observed in Guillain–Barré syndrome.
IgM. IgM antibodies have been detected in early work, but their significance in disease is controversial.
Notes and References
- Gregson NA, Pytharas M, Leibowitz S . The reactivity of anti-ganglioside antiserum with isolated cerebellar cells . Biochem. Soc. Trans. . 5 . 1 . 174–5 . 1977 . 70385 . 10.1042/bst0050174.
- Willison HJ, O'Hanlon G, Paterson G . Mechanisms of action of anti-GM1 and anti-GQ1b ganglioside antibodies in Guillain–Barré syndrome . J. Infect. Dis. . 176 Suppl 2 . S144–9 . 1997 . 9396699 . 10.1086/513799 . etal. free .
- Ho TW, Willison HJ, Nachamkin I . Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain–Barré syndrome . Ann. Neurol. . 45 . 2 . 168–73 . 1999 . 9989618 . 10.1002/1531-8249(199902)45:2<168::AID-ANA6>3.0.CO;2-6 . etal.
- Ang CW, Yuki N, Jacobs BC . Rapidly progressive, predominantly motor Guillain–Barré syndrome with anti-GalNAc-GD1a antibodies . Neurology . 53 . 9 . 2122–7 . 1999 . 10599792 . 10.1212/wnl.53.9.2122. etal.
- Chapman J, Sela BA, Wertman E, Michaelson DM . Antibodies to ganglioside GM1 in patients with Alzheimer's disease . Neurosci. Lett. . 86 . 2 . 235–40 . 1988 . 3368123 . 10.1016/0304-3940(88)90577-0 .
- Gregson NA, Koblar S, Hughes RA . Antibodies to gangliosides in Guillain–Barré syndrome: specificity and relationship to clinical features . Q. J. Med. . 86 . 2 . 111–7 . 1993 . 8464986 .
- Irie S, Saito T, Kanazawa N . Relationships between anti-ganglioside antibodies and clinical characteristics of Guillain–Barré syndrome . Intern. Med. . 36 . 9 . 607–12 . 1997 . 9313102 . 10.2169/internalmedicine.36.607 . etal. free .
- Bansal AS, Abdul-Karim B, Malik RA . IgM ganglioside GM1 antibodies in patients with autoimmune disease or neuropathy, and controls . J. Clin. Pathol. . 47 . 4 . 300–2 . 1994 . 8027366 . 10.1136/jcp.47.4.300 . 501930 . etal.
- Salih AM, Nixon NB, Gagan RM . Anti-ganglioside antibodies in patients with rheumatoid arthritis complicated by peripheral neuropathy . Br. J. Rheumatol. . 35 . 8 . 725–31 . 1996 . 8761183 . 10.1093/rheumatology/35.8.725 . etal.
- García Guijo C, García-Merino A, Rubio G . Presence and isotype of anti-ganglioside antibodies in healthy persons, motor neuron disease, peripheral neuropathy, and other diseases of the nervous system . J. Neuroimmunol. . 56 . 1 . 27–33 . 1995 . 7822479 . 10.1016/0165-5728(94)00129-C .
- https://jamanetwork.com/journals/jamaneurology/fullarticle/2818518
- O'Hanlon GM, Plomp JJ, Chakrabarti M . Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal . Brain . 124 . Pt 5 . 893–906 . 2001 . 11335692 . 10.1093/brain/124.5.893 . etal. free .
- Sinha S, Prasad KN, Jain D, Pandey CM, Jha S, Pradhan S . Preceding infections and anti-ganglioside antibodies in patients with Guillain–Barré syndrome: a single centre prospective case-control study . Clin. Microbiol. Infect. . 13 . 3 . 334–7 . 2007 . 17391394 . 10.1111/j.1469-0691.2006.01636.x. free .
- Yuki N, Handa S, Tai T . Ganglioside-like epitopes of lipopolysaccharides from Campylobacter jejuni (PEN 19) in three isolates from patients with Guillain–Barré syndrome . J. Neurol. Sci. . 130 . 1 . 112–6 . 1995 . 7544402 . 10.1016/0022-510X(95)00045-4 . etal.
- Rees JH, Gregson NA, Hughes RA . Anti-ganglioside GM1 antibodies in Guillain–Barré syndrome and their relationship to Campylobacter jejuni infection . Ann. Neurol. . 38 . 5 . 809–16 . 1995 . 7486873 . 10.1002/ana.410380516.
- Volta U, De Giorgio R, Granito A . Anti-ganglioside antibodies in coeliac disease with neurological disorders . Digestive and Liver Disease . 38 . 3 . 183–7 . 2006 . 16458087 . 10.1016/j.dld.2005.11.013. etal.
- Alaedini A, Latov N . Transglutaminase-independent binding of gliadin to intestinal brush border membrane and GM1 ganglioside . J. Neuroimmunol. . 177 . 1–2 . 167–72 . 2006 . 16766047 . 10.1016/j.jneuroim.2006.04.022.
- Mathiesen T, von Holst H, Fredrikson S . Total, anti-viral, and anti-myelin IgG subclass reactivity in inflammatory diseases of the central nervous system . J. Neurol. . 236 . 4 . 238–42 . 1989 . 2760636 . 10.1007/BF00314506 . etal.
- McCombe PA, Wilson R, Prentice RL . Anti-ganglioside antibodies in peripheral neuropathy . Clinical and Experimental Neurology . 29 . 182–8 . 1992 . 1343861 .
- Willison HJ, Chancellor AM, Paterson G . Antiglycolipid antibodies, immunoglobulins and paraproteins in motor neuron disease: a population based case-control study . J. Neurol. Sci. . 114 . 2 . 209–15 . 1993 . 8445403 . 10.1016/0022-510X(93)90300-N . etal.